PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

NCT02571725 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Neoplasms

Interventions

DRUG: Olaparib
DRUG: Tremelimumab

Sponsor

New Mexico Cancer Research Alliance